The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
Glofitamab: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
Obinutuzumab: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Study summary
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Be diagnosed as R/R DLBCL
* Participants who will be treated with glofitamab (known as being recommended and having the intention to be treated with glofitamab at the time of signing informed consent) or have initiated glofitamab treatment within 6 months prior to enrollment and after the indication approval will be observed in this study.
Exclusion Criteria:
* Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Primary outcome measure(s)
Progression free survival (PFS) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma — Baseline up to end of study (EOS) (approximately 48 months)
Trial sites (1)
Facility
City
Region
Status
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.